Regeneron to Provide Otarmeni Free and Match U.S. Drug Prices to Developed Nations
Regeneron will provide Otarmeni gene therapy for hearing loss free to U.S. patients and lower Medicaid prices to overseas levels. It will align U.S. prices of future medicines with those countries, offer Praluent at most-favored nation rates via TrumpRx.gov and secure tariff relief with $9 billion pledged to U.S. R&D.
1. Government Pricing Agreement
Regeneron has agreed to lower Medicaid prices in the U.S. based on rates in other developed countries and will align the U.S. launch prices of its future medicines with those nations. The deal addresses prior calls to equilibrate global drug costs while aiming to preserve innovation funding and competitive U.S. market access.
2. Otarmeni Gene Therapy Program
Otarmeni (lunsotogene parvec-cwha), recently approved for severe hearing loss due to otoferlin gene variants, will be provided free to eligible American patients. This marks Regeneron’s first gene therapy deployment under the new agreement, expanding access for an ultra-rare condition without cost barriers.
3. Praluent Patient Access
Regeneron will use the TrumpRx.gov platform to offer Praluent (alirocumab) at most-favored nation prices directly to patients, enabling cardiovascular therapy at lower out-of-pocket costs. This program targets improved affordability and broader uptake among eligible users outside traditional insurance channels.
4. Tariff Relief and R&D Investments
Under the arrangement with the U.S. Department of Commerce, Regeneron will receive three years of tariff relief and has committed over $9 billion to expand domestic R&D and manufacturing infrastructure. These investments aim to bolster U.S.-based biologics production and sustain innovation pipelines.